A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass
Heart Disease, Renal Insufficiency
About this trial
This is an interventional prevention trial for Heart Disease focused on measuring cardiopulmonary bypass, renal insufficiency, cardiac surgery, n-acetylcysteine
Eligibility Criteria
Inclusion Criteria: The study includes those patients with preoperative renal dysfunction (serum creatinine level 140 μmol/L or greater or a calculated glomerular filtration rate of 50 mL/min or less), or a risk factor score for postoperative renal dysfunction that adds up to 6 or more based on the following scale: Score Risk Factor: 3 scheduled for redo cardiac surgery 3 scheduled for valve surgery 2 age greater than 69 at time of surgery 2 known diabetic (Type I or II) 2 congestive heart failure 2 treated hypertension 2 chronic obstructive pulmonary disease 2 preoperative stroke 1 left ventricular function -grade 3 or 4 (seen on echo or angiogram) 1 New York Heart Association Class 3 or 4 Exclusion Criteria: Patient is participating in another trial Patient has received NAC in the past 48 hours. Patient has allergy to N-acetylcysteine. Patient scheduled for off-pump surgery or an extracardiac procedure (pericardiectomy etc.) Patient requires emergent surgery Patient scheduled for a procedure involving circulatory arrest. Patient requires chronic dialysis (peritoneal or hemodialysis) Patient unable to give informed consent (dementia, does not speak English, etc.) Patient has a recent history of cancer (in last five years) or untreated cancer